Walk into the Rock Health Capital office at 301 Howard and you will not find a tourist. Bill Evans has been inside this industry long enough to remember when "digital health" was two words that did not belong together. He ran the parent brand as CEO and managing director from 2016 through 2020. He launched Navify, Roche's oncology decision-support business unit, before that. He wrote software in Silicon Valley in the late 1990s, before that. He started at Goldman Sachs the year he graduated from Harvard, before all of it.
The thread, if there is one, runs through systems. Evans tends to show up where engineering and biology argue with each other. He picks a side. Then he ships.
Rock Health Capital opened for business in July 2022. The fund leads pre-seed through Series A rounds with checks between $500,000 and $3 million. The thesis is narrow on purpose: remarkable founders working at the intersection of healthcare and technology, with a special soft spot for virtual cardiology, femtech and maternal outcomes, and the slow grind of getting AI inside clinical workflows without breaking them.
That narrowness is the product. Generalists tour healthcare. Evans lives there. He has run a P&L inside a pharma giant. He has stood across the table from hospital systems. He has watched a regulator move slower than a roadmap. The pitch to founders is that the firm shows up with both money and scar tissue.
The three-pronged thing
Rock Health Capital is not a fund pretending to be a platform. It is a platform that contains a fund. The other two prongs are Rock Health Advisory, the strategy practice that consults Fortune 500 companies in digital health, and an equity-focused nonprofit arm that runs original survey research on founder demographics and uses the data to direct capital toward underrepresented digital health innovators.
Portfolio companies get pulled into the advisory orbit. Advisory clients get pulled into the portfolio orbit. The nonprofit publishes the data that everyone else cites. The flywheel is unfashionably simple: tell the truth about who is building, sell access to the people who buy, write checks where it matters.
Our portfolio is our legacy.- Bill Evans, Rock Health Capital
From Goldman to Genentech
Evans graduated from Harvard with a B.A. in economics and took the well-trodden path to Goldman Sachs. That path bent. By the late 1990s he was in Silicon Valley writing code during the original startup boom, the one with the WB-11 ads and the gold-rush hiring practices. He learned what software does to industries before software did anything to healthcare.
From 2003 to 2014 he held a sequence of leadership roles at Genentech, the South San Francisco biotech that arguably invented the modern industry. Then Roche acquired Genentech in full and Evans moved into the parent company, eventually becoming senior director responsible for launching Navify, Roche Diagnostics' oncology decision-support business unit. Navify was, and remains, a real product inside a real cancer workflow. Building it taught him a thing pure financiers never quite learn: how hard it is to actually move a clinician's hand.
The Rock Health years
In 2016 Evans became CEO and managing director of Rock Health, the seed-stage digital health firm that built the brand of the sector. Halo Health Solutions, the original entity, had been issuing reports, hosting summits, and minting category definitions since 2010. Evans inherited a brand with a strong voice and a market that was just starting to take itself seriously.
He stayed four years. By the time he stepped out of the operating role, "digital health" had become a verb venture investors used in sentences with conviction. He stepped back, then spun the venture vehicle into its own entity. Rock Health Capital is what came next.
The portfolio
Rock Health Capital leads rounds. That matters. Leading means setting terms, taking board seats, doing the un-fun work of pricing a round when no one wants to go first. For founders building in healthcare, where regulatory timelines are slower than a venture clock and clinical evidence requires patience that capital does not naturally possess, having a lead investor with operating chops is the difference between a company that survives the messy middle and one that does not.
The fund invests across virtual care, AI-driven clinical tooling, femtech and maternal outcomes, enterprise SaaS for providers and payers, and the slow business of moving data through systems that were not built to share it. Sector-focused. Stage-focused. Geography-focused on the United States. The discipline is the moat.
The arc, in bars
The Teamster
Evans is a member of the Teamsters Union. That sentence does not show up next to many venture capitalists in San Francisco. It is the kind of detail that makes a bio interesting and a partner interesting in equal measure. Whatever the origin story, the membership is real and it travels with him.
His bio also lists, with a straight face, that he has lived through The Drive, The Fumble, The Shot, The Move, The Decision, and The Drought. Cleveland sports fans will nod. Everyone else needs to look up at least four of those. The point is the same either way: this is a person who knows how to wait for a payoff.
He is a husband and father of four. He camps. He sits on advisory rosters with a calm, plain affect that is uncommon in a city where every other partner has a personal newsletter. His public quotes are rarer than his investments, and his investments are not in short supply.
What he is building now
The current job is to write the first check in companies that will, with luck and patience, become the standard infrastructure of healthcare delivery. The smaller question is which companies. The larger question is what changes when the right ones win.
Rock Health Capital's bet is that the next decade of healthcare gets rewritten in three places. One: virtual specialty care that finally gets reimbursed at the rates the math requires. Two: women's health and maternal outcomes, where the gap between what we know and what we deliver is widest. Three: AI applied not to billing but to the actual decisions clinicians make at the bedside, with the kind of evidence base that a real regulator can sign off on.
Bill Evans is not the loudest voice in the room about any of those things. He is the person who already wrote the check.
From shipping code in the dot-com boom to writing first checks for digital health founders - the throughline is the same: build the system the industry needs next.- Editorial note
The shape of the platform
Most venture funds in healthcare pick a swim lane: payer-tech, provider-tech, biotech, devices. Rock Health Capital picks an audience. The audience is operators who want to build inside the seam between technology and care, and the platform around the fund exists to make those operators easier to support. Advisory clients become customers for the portfolio. Portfolio companies become reference customers for the advisory. The nonprofit produces the data that frames the whole conversation.
It is a structure that only works if the person at the top has lived in all three rooms. Evans has. He has sold strategy to executives at Roche. He has run the brand that runs the conference. He has now spent the better part of four years writing checks into companies that will live or die on whether they can navigate hospitals, regulators, and reimbursement at the same time.
The bet, in the end, is that healthcare changes from the inside. The fund exists to find the people doing the changing and to make sure they have enough capital, evidence, and access to land the planes they are building. Evans is the pilot's pilot. He has flown enough of these to know where the turbulence is.